Oxford BioMedica   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Oxford United Kingdom (1995)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2004
NCT00259844
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Oxford BioMedica | Oxford Biomedical Technologies, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Renal Cell (Phase 3)

Colorectal Neoplasms (Phase 2)

Fallopian Tube Neoplasms (Phase 2)

Kidney Neoplasms (Phase 3)

Macular Degeneration (Phase 1)

Neoplasm Metastasis (Phase 2)

Ovarian Neoplasms (Phase 2)

Parkinson Disease (Phase 2)

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial APIs: 10